Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
about
New insights into the possible role of bacteriophages in host defense and diseaseB-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?Comparison of diagnostic criteria for common variable immunodeficiency disorderMissense mutations affecting a conserved cysteine pair in the TH domain of Btk.Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA)CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.Antibody producing capacity to the bacteriophage phi X174 in rheumatoid arthritis.Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndromeCTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.Comèl-Netherton syndrome defined as primary immunodeficiency.Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates.B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells.Post-transplantation B cell function in different molecular types of SCIDEffect of rituximab on human in vivo antibody immune responses.Bacteriophage biocontrol in animals and meat products.Biological gene delivery vehicles: beyond viral vectors.New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections.Laboratory diagnosis of primary immunodeficiencies.Diagnostic Immunization with Bacteriophage ΦX 174 in Patients with Common Variable Immunodeficiency/Hypogammaglobulinemia.Safety and efficacy of phage therapy via the intravenous route.Phage Therapy in the Era of Synthetic Biology.Management of patients with primary immune deficiency syndromes.Proteasome inhibitors enhance bacteriophage lambda (lambda) mediated gene transfer in mammalian cells.Immunoreconstitution by peripheral blood leukocytes in adenosine deaminase-deficient severe combined immunodeficiency.PhiXing-it, displaying foreign peptides on bacteriophage ΦX174.Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment.Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections.Applications for Bacteriophage Therapy during Pregnancy and the Perinatal Period.The immune response to thetaX 174 in man. I. Primary and secondary antibody production in normal adults.Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.Defective surface expression of attractin on T cells in patients with common variable immunodeficiency (CVID)Immunocompatibility of Bacteriophages as Nanomedicines
P2860
Q24804005-2B5E1C3C-0895-4330-A2B6-F8BFCD10DDECQ26828763-CC859B39-3318-4729-BAA3-D06B54A2593FQ26859119-55E9575F-5BE1-4EAA-8951-10F863A4005DQ30176453-E5A01B23-937F-4D2C-BBCF-1A94A7499C0DQ30194173-1FAC6A13-A394-4A48-9265-83D95E379457Q30453877-DCCF18CA-3FC7-4801-9344-8B92A38CD410Q33560504-5C3CC3A8-84F7-4A96-9EDE-EC2CD127D314Q33843738-0EC9D8FE-6427-4899-ABD1-13B2FA5BE073Q33855058-1FFAFBD4-B392-4490-8C3C-9E0E75A11B9DQ34602577-A8917408-9993-448F-82BC-4355A4866602Q34997608-11FA9893-2F7E-4818-ADB0-F869A9C67C18Q36250598-6B74DD73-6C93-4C59-916F-FA85F82CBB9EQ36362252-26D5130C-D690-4083-AB09-04E2D3F3C872Q36546267-5079AD08-30EC-4C64-89D4-76AA8FDB284CQ36860483-F60249F5-3C35-48B7-9893-29F301DA3451Q37273445-8F35F0AE-2239-44E0-8C8F-7445779434E8Q37412239-8DFDD067-606C-4318-A5AF-8FB8344EA65AQ38121956-2304833C-2391-48C0-B9E0-A321D2545477Q38140012-4802980D-C75A-4D80-B9BF-AFFBAE0B76DEQ38191164-5FA44ADA-6B63-4301-A2FE-7EF6122E40F8Q38249185-2F5D7563-3477-4ABC-BDA5-148BA9AB6AC3Q38675765-8031507B-3D73-4C8A-95E4-4C728D08BAD2Q38915649-8EB896DC-074C-498C-B4CA-1A26C4708C4FQ39871435-B956E99C-0352-4E42-8C1D-C5257EBEBA2AQ39907814-1AFAE9B3-C93D-4B9E-AFE8-4A9342773376Q40688240-4D8B41AB-4021-4983-A102-80F3BC387111Q40876140-7F27B810-93EE-4192-9505-5EF9BD0C98FDQ41872915-229371FF-F5FA-4281-9D60-D36BE9977324Q42207657-9E315745-EDF2-4F1E-B44F-B6C537273C29Q47918127-8ED46575-6DED-4F91-A92F-84798306ACB9Q49631079-035F9CD4-C59F-4909-BEFE-63578BFE1DF8Q52253781-9B6AEB7B-9721-40F7-93C6-6DD773647777Q54116803-C13B236D-D73F-4B94-8D28-FC0D21D53B0FQ54423024-92AA38A2-7FD9-43B0-B0B6-D85767515A62Q58443749-8E837C5A-6BA8-4A63-8FB8-5A5EFBB3E9F5Q58910820-84F2A3B1-FD48-47CF-ADC5-74FC67B73E0D
P2860
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
description
1971 nî lūn-bûn
@nan
1971 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1971 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1971年の論文
@ja
1971年論文
@yue
1971年論文
@zh-hant
1971年論文
@zh-hk
1971年論文
@zh-mo
1971年論文
@zh-tw
1971年论文
@wuu
name
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@ast
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@en
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@nl
type
label
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@ast
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@en
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@nl
prefLabel
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@ast
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@en
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@nl
P2093
P2860
P356
P1476
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.
@en
P2093
P2860
P304
P356
10.1172/JCI106756
P407
P577
1971-12-01T00:00:00Z